683 Capital Management, LLC
13F filer · CIK 1404574 · New York, NY
Summary
683 Capital Management, LLC reported $2.04B across 153 positions in its 13F for 2026 Q2, filed Aug 14, 2026. The largest holdings are COF (3.6%), CVNA (2.4%), ANAB (2.2%). Versus 2026 Q1, leaving options aside, it opened 19 new positions, added to 29, trimmed 37 and sold out of 99.
Reported value$2.04B
Positions153incl. options
Report period2026 Q2
FiledAug 14, 2026
New positions19
Added29
Trimmed37
Sold out99
Top 25 holdings
By reported value, options listed separately · change vs 2026 Q1
Weight 3.6%Value $73.23MPrice $196.46Shares 365K -2.67%Since Jun 30 -2.07%
Weight 2.4%Value $49.37MPrice $63.62Shares 750K +383.87%Since Jun 30 -3.34%
Weight 2.2%Value $44.55MPrice $50.37Shares 660K +5.60%Since Jun 30 -25.38%
Weight 2.0%Value $40.72MPrice $95.75Shares 470K -1.05%Since Jun 30 +10.51%
BRIDGEBIO PHARMA INCNo ticker matchHold
Weight 1.9%Value $38.78MPrincipal $21.75M
Weight 1.9%Value $37.83MPrice $181.97Shares 250K +11.11%Since Jun 30 +20.25%
Weight 1.9%Value $37.74MPrice $189.38Shares 165K +3.13%Since Jun 30 -17.19%
Weight 1.8%Value $36.14MPrice $35.78Shares 690K -10.97%Since Jun 30 -31.68%
Weight 1.7%Value $35.55MPrice $140.97Shares 290K -18.31%Since Jun 30 +15.00%
Weight 1.5%Value $31.07MPrice $11.13Shares 2.30M -6.12%Since Jun 30 -17.62%
Weight 1.4%Value $28.76MPrice $3.64Shares 4.95M +1.02%Since Jun 30 -37.35%
Weight 1.3%Value $26.48MPrice $24.51Shares 575K +15.00%Since Jun 30 -46.79%
Weight 1.1%Value $22.98MPrice $29.28Shares 1.28M -16.37%Since Jun 30 +63.03%
Weight 1.1%Value $22.74MPrice $18.15Shares 1.10M +41.94%Since Jun 30 -12.19%
Weight 1.0%Value $21.38MPrice $56.19Shares 389K -34.05%Since Jun 30 +2.28%
Weight 1.0%Value $20.07MPrice $7.36Shares 1.85MSince Jun 30 -32.17%
Weight 0.9%Value $17.58MPrice $39.72Shares 615KSince Jun 30 +38.98%
Weight 0.8%Value $16.44MPrice $75.76Shares 200K -11.11%Since Jun 30 -7.83%
Weight 0.8%Value $16.00MPrice $18.64Shares 1.01M -3.81%Since Jun 30 +17.68%
Weight 0.8%Value $15.47MPrice $392.73Shares 40KSince Jun 30 +1.55%
Weight 0.7%Value $15.09MPrice $35.98Shares 750KSince Jun 30 +78.83%
Weight 0.7%Value $15.02MPrice $10.50Shares 1.50M +1.69%Since Jun 30 +5.21%
Weight 0.7%Value $14.06MPrice $18.64Shares 783K +4.33%Since Jun 30 +3.73%
Weight 0.7%Value $13.30MPrice $374.94Shares 32KSince Jun 30 -9.79%
Weight 0.6%Value $12.94MPrice $98.62Shares 135KSince Jun 30 +2.91%
| Stock | Weight | Value | Since Jun 30 | Shares change | Action |
|---|---|---|---|---|---|
| 3.6% | $73.23M | -2.07% | -2.67% | Trim | |
| 2.4% | $49.37M | -3.34% | +383.87% | Add | |
| 2.2% | $44.55M | -25.38% | +5.60% | Add | |
| 2.0% | $40.72M | +10.51% | -1.05% | Trim | |
| BRIDGEBIO PHARMA INCNo ticker match | 1.9% | $38.78M | — | — | Hold |
| 1.9% | $37.83M | +20.25% | +11.11% | Add | |
| 1.9% | $37.74M | -17.19% | +3.13% | Add | |
| 1.8% | $36.14M | -31.68% | -10.97% | Trim | |
| 1.7% | $35.55M | +15.00% | -18.31% | Trim | |
| 1.5% | $31.07M | -17.62% | -6.12% | Trim | |
| 1.4% | $28.76M | -37.35% | +1.02% | Add | |
| 1.3% | $26.48M | -46.79% | +15.00% | Add | |
| 1.1% | $22.98M | +63.03% | -16.37% | Trim | |
| 1.1% | $22.74M | -12.19% | +41.94% | Add | |
| 1.0% | $21.38M | +2.28% | -34.05% | Trim | |
| 1.0% | $20.07M | -32.17% | — | Hold | |
| 0.9% | $17.58M | +38.98% | — | New | |
| 0.8% | $16.44M | -7.83% | -11.11% | Trim | |
| 0.8% | $16.00M | +17.68% | -3.81% | Trim | |
| 0.8% | $15.47M | +1.55% | — | Hold | |
| 0.7% | $15.09M | +78.83% | — | New | |
| 0.7% | $15.02M | +5.21% | +1.69% | Add | |
| 0.7% | $14.06M | +3.73% | +4.33% | Add | |
| 0.7% | $13.30M | -9.79% | — | Hold | |
| 0.6% | $12.94M | +2.91% | — | New |
Weight is the share of the reported 13F value, including options at notional value. “Since Jun 30” compares the latest close with the quarter-end price implied by the filing (value ÷ shares).
Largest buys in 2026 Q2
Largest sells in 2026 Q2
Options
Notional value, listed apart from stocks · top 10 of 25
Source: SEC Form 13F, values as reported by the filer. Filings lag up to 45 days after quarter end and cover only certain long positions. Research only, not investment advice.